Additionally, in an open-label clinical trial, it was demonstrated that subcutaneous IGF-1 treatment in SCA3/MJD patients could increase the SARA score after only 8 months; however, this benefit faded after 10–20 months [68]. The gene discussed is IGF1; the disease is Spinocerebellar ataxia type 3.